Open access
Aug 2026
Transforming clinical apheresis waste into a renewable source of patient-derived CD34+ hematopoietic stem cell biobank for beta-hemoglobinopathy research and therapeutic discovery
Clinical apheresis waste is used to generate a single-center biobank of high-quality, research-grade CD34+ HSPCs from patients with sickle cell disease and beta-thalassemia, addressing a recognized gap in the hemoglobinopathy pipeline.
Jun Liu, Shin-young Park, Hirotomo Nakahara et al.
· bioRxiv · 0 citations